(Q47253208)

12 January 2018

title

Sample size considerations for superiority trials in systemic lupus erythematosus (SLE). (English)

1 reference

12 January 2018

systemic lupus erythematosus

main subject

1 reference

A D Moore

1

1 reference

12 January 2018

L Joseph

series ordinal

2

1 reference

12 January 2018

publication date

1 January 1999

1 reference

12 January 2018

published in

Lupus

1 reference

12 January 2018

volume

8

1 reference

12 January 2018

issue

8

1 reference

12 January 2018

page(s)

612-619

1 reference

12 January 2018

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

cites work

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

Introduction to sample size determination and power analysis for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

Approaches to sample size estimation in the design of clinical trials--a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

Placing trials in context using Bayesian analysis. GUSTO revisited by Reverend Bayes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

Sample sizes for constructing confidence intervals and testing hypotheses

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

The importance of beta, the type II error and sample size in the design and interpretation of the randomized control trial. Survey of 71 "negative" trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

Evidence for the Superiority of Immunosuppressive Drugs and Prednisone over Prednisone Alone in Lupus Nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

Trends in the incidence and mortality of systemic lupus erythematosus, 1950-1992.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

A randomized study of the effect of withdrawing hydroxychloroquine sulfate in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

Termination of a clinical trial with no treatment group difference: the Lupus Nephritis Collaborative Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

Planning the size and duration of a clinical trial studying the time to some critical event

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

Estimating sample sizes for binary, ordered categorical, and continuous outcomes in two group comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

Sample size calculations for ordered categorical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

The determination of sample size in treatment-control comparisons for chronic disease studies in which drop-out or non-adherence is a problem

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

Sample izes for medical trials with special reference to long-term therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

Bayesian and mixed Bayesian/likelihood criteria for sample size determination

21 January 2018

1 reference

https://api.crossref.org/works/10.1191%2F096120399680411326

10.1191/096120399680411326

21 January 2018

Identifiers

DOI

1 reference

12 January 2018

PubMed ID

10568897

1 reference

12 January 2018